Intellia Therapeutics Announces Promising Phase 3 Trial Results for Lonvo-z, Plans for 2027 U.S. Launch

Reuters
16 Jun
Intellia <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Promising Phase 3 Trial Results for Lonvo-z, Plans for 2027 U.S. Launch

CAMBRIDGE, Mass. June 15, 2025 (GLOBE NEWSWIRE) - Intellia Therapeutics, Inc. (NASDAQ:NTLA), a clinical-stage gene editing company, has announced three-year follow-up data from the Phase 1 portion of its ongoing Phase 1/2 study in patients with hereditary angioedema $(HAE)$ using a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). The results were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, United Kingdom. The Phase 3 HAELO trial, a global, randomized, double-blind, placebo-controlled study, has completed screening ahead of schedule, with over half of the participants screened in the United States. Intellia plans to report the outcomes of the Phase 3 study in the first half of 2026 and aims to submit a biologics license application $(BLA.AU)$ in 2026 to support a U.S. launch in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intellia Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-141087), on June 16, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10